TGF-β is well-established as a driver of the epithelial-mesenchymal transition (EMT) and the mesenchymal phenotype in cancer, and there is a dire need in oncology for therapies targeting mesenchymal cancers with high TGF-β activity. The gene discussed is TGFB1; the disease is cancer.